Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13, 146

Dysregulation of Over-Expressed IL-32 in Colorectal Cancer Induces Metastasis

Affiliations

Dysregulation of Over-Expressed IL-32 in Colorectal Cancer Induces Metastasis

Yi Yang et al. World J Surg Oncol.

Abstract

Background: Interleukin (IL)-32 is a described intracellular pluripotent pro-inflammatory mediator, characterized by the signaling of NF-κB and STAT3.

Methods: Our study investigated whether IL-32 expression has clinical significance in the metastases of colorectal cancer (CRC). A total of 70 CRC patients were enrolled, 47 cases of which were single CRC organic metastasis lesions while the rest of which were primary CRC lesions (T4NxM0). IL-32 expression was detected by immunohistochemistry, and the correlation between IL-32 expression and CRC metastases was analyzed.

Results: The positive rates of IL-32 in the CRC organic metastasis group were more severe than those in the primary CRC group (P < 0.05). The positive rate of IL-32 in primary CRC with lymph node metastasis was more severe than that of IL-32 in primary CRC without lymph node metastasis (P < 0.05).

Conclusions: The level of IL-32 expression could influence the N grade of CRC. Thus, IL-32 expression may stimulate the organic metastasis and the lymph node metastasis of CRC.

Figures

Figure 1
Figure 1
IL-32 staining scored 0 (A); IL-32 staining scored 1+ (B); IL-32 staining scored 2+ (C); and IL-32 staining scored 3+ (D) magnification × 100.
Figure 2
Figure 2
The relationship between N grade of primary CRC and OD value.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61C:69–90. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs. 2001;10:1011–9. doi: 10.1517/13543784.10.6.1011. - DOI - PubMed
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc Suppl J Int Canc. 2010;127:2893–917. doi: 10.1002/ijc.25516. - DOI - PubMed
    1. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg. 2002;89:1557–62. doi: 10.1046/j.1365-2168.2002.02276.x. - DOI - PubMed

Publication types

MeSH terms

Feedback